

European Heart Journal

Volume 43 No. 14 April 2022

ISSUE @ A GLANCE



Lipid lowering beyond statins and methodological issues in cardiovascular clinical trials
F. Crea

1365

CardioPulse

South–South Partnerships in Cardiovascular Research in Africa: empowering the next generation of cardiovascular researchers

A. Mocumbi, E. Lichucha, and K. Sliwa

1369

Conversing with Nobel Laureate Ferid Murad

M. Nicholls

1372

Meet Franz Weidinger MD, ESC President Elect

J. Ozkan

1375

Weekly Journal Scan

Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs

M. Volpe and C. Patrono

1377

FOCUS ISSUE ON CLINICAL TRIALS

STATE OF THE ART REVIEW

Kidney function assessment and endpoint ascertainment in clinical trials

M.S. Khan, G.L. Bakris, M. Packer, I. Shahid, S.D. Anker, G.C. Fonarow, C. Wanner, M.R. Weir, F. Zannad, and J. Butler

1379

CLINICAL RESEARCH



Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

J.-C. Tardif, E. Karwatowska-Prokopczuk, E.S. Amour, C.M. Ballantyne, M.D. Shapiro, P.M. Moriarty, S.J. Baum, E. Hurh, V.J. Bartlett, J. Kingsbury, A.L. Figueroa, V.J. Alexander, J. Tami, J.L. Witztum, R.S. Geary, L.S.L. O'Dea, S. Tsimikas, and D. Gaudet; for the Olezarsen Study Investigators

1401

Editorial

Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?

R.A. Hegele

1413



Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

Writing Committee: E. Sammons, J.C. Hopewell, F. Chen, W. Stevens, K. Wallendszus, E. Valdes-Marquez, R. Dayanandan, C. Knott, K. Murphy, E. Wincott, A. Baxter, R. Goodenough, M. Lay, M. Hill, S. Macdonnell, G. Fabbri, D. Lucci, M. Fajardo-Moser, S. Brenner, D. Hao, H. Zhang, J. Liu, B. Wuhan, S. Mosegaard, W. Herrington, C. Wanner, C. Angermann, G. Ertl, A. Maggioni, P. Barter, B. Mihaylova, Y. Mitchel, R. Blaustein, S. Goto, J. Tobert, P. DeLuca, Y. Chen, Z. Chen, A. Gray, R. Haynes, J. Armitage, C. Baigent, S. Wiviott, C. Cannon, E. Braunwald, R. Collins, L. Bowman, and M. Landray; on behalf of the REVEAL Collaborative Group

1416

Editorial

CETP inhibitors revisited

U. Laufs and T. Speer

1425

Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI

B. Pitt, J.P. Ferreira, and F. Zannad

1428

Patient partnership in cardiovascular clinical trials

F. Zannad, C. Chauhan, P.O. Gee, Sr., N. Hartshorne-Evans, A.F. Hernandez, M.K. Mann, R. Martinez, and R. Mehran

1432

CARDIOVASCULAR FLASHLIGHT

Blunt cardiac trauma induced all types of left ventricular trauma in a 3-year-old girl

J. Zhu, B. Huang, E.-P. Xi, and X.-H. Gao

1438

Recurrent acute pericarditis diagnosed by extra-cellular volume maps

B. McDonough, N. Perepelova, P. Kellman, J.B. Galloway, and S. Rosmini

1440

Isolated double-orifice mitral valve: an atypical morphology in adult patient

A. Malagoli, S. Chiusolo, and S. Tondi

1442

With thanks to

for the pod

oup.com/eurheartj

The Focus

This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>

University

Open Access Paper

they sever

the below

For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>

200 mil

100-200 The

ray func

in clinical

elemental

tracted a

variables

where the

and head

were you

(2-1000)

Second

were sh

T2DM

did not

trial

15% R

low

of ch

ney

trial

ferm

slope

Aut